Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial looked at a medication called relamorelin (given as a 10 microgram injection) compared to a placebo (an inactive injection) in people with diabetic gastroparesis — a condition where the stomach empties more slowly than normal due to diabetes. A total of 467 participants started the main 40-week treatment phase (236 on placebo, 231 on relamorelin), and a smaller group of 193 participants then went on to a further 6-week follow-up period. The trial tracked participants' daily symptom scores covering nausea, abdominal pain, bloating, and the feeling of fullness after eating, as well as vomiting episodes. The reported data shows that at the start of the trial, both groups had very similar average total symptom scores of around 24.8–24.9 out of a possible 40 (where higher scores mean worse symptoms). After 12 weeks, both groups showed a decrease in their scores — the placebo group's score fell by about 11.9 points on average, and the relamorelin group's score fell by about 11.2 points. For the vomiting measure, 29.4% of the placebo group and 21.4% of the relamorelin group met the criterion of having no vomiting episodes across the last six of those first 12 weeks. The reported data also shows that for the secondary measures — including the proportion of participants who had meaningful improvements in nausea, abdominal pain, bloating, and post-meal fullness — the figures were broadly similar between the two groups, ranging from roughly 36% to 46% depending on the symptom and group. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Gastroparesis Trial, Terminated
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You must have taken part in one of two related studies (NCT03285308 or NCT03426345) and completed it successfully, meeting all of that study's requirements.
- You must be able to read and sign a consent form before any study activities begin, and be willing and able to follow all study procedures.
- In the opinion of the study doctor, you must have followed the rules and procedures of the previous related study well enough.
Who may not be able to join:
- You are not willing or able to follow the rules about which other medicines you can or cannot take during the study.
- You are planning to take part in another study involving an experimental drug or medical device at any point during this trial.
- You currently have an unresolved side effect or a concerning finding from a physical exam, blood/lab test, or heart tracing (ECG) that the study doctor believes would prevent you from safely completing the study.
- You have kidney, liver, or heart/lung disease, or any other condition that the study doctor believes could make it unsafe for you to participate or could affect the study results (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Wieslaw Bochenek, Allergan
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
3 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Change From Baseline to Week 12 in the Weekly Diabetic Gastroparesis Symptom Severity Score (DGSSS) of the Treatment Period; Percentage of Participants Meeting the Vomiting Responder Criterion During Each of the Last 6 Weeks of the First 12-weeks of the Treatment Period
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.